Illustration of bows being shot at a cancer cell to depict target cancer therapy

Wes Mountain / The Pharmaceutical Journal

Engineering precision: developing the next generation of antibody drug conjugates

Researchers are working to create a new generation of these targeted cancer therapies to improve efficacy and minimise off-target adverse effects.

When results from the ‘EV-302’ bladder cancer trial were presented at the European Society for Medical Oncology annual meeting in October 2023, they received a standing ovation. The study compared standard chemotherapy with enfortumab vedotin (Padcev; Astellas and Seagen) — a novel antibody drug conjugate (ADC) — given with the immunotherapy drug pembrolizumab in almost 900 people.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated